Moderna’s Pipeline Expansion Has Jim Cramer Singing a Fresh Tune
CNBC’s Jim Cramer has a new favorite pick in the biotech space: Moderna. And it’s not just because of the company’s historic Covid-19 vaccine.
Moderna’s expanding pipeline of treatments for cancer and other diseases has finally given investors a reason to buy the stock, Cramer said on CNBC. It’s been a long time coming, with the company’s stock prices plummeting in the two years following the vaccine’s release. Now, with multiple pipelines in the works, investors are taking notice.
New Horizons for Moderna
The company’s mRNA technology has proven to be a versatile tool in developing treatments beyond infectious diseases. According to Cramer, Moderna’s mRNA-based treatments for diseases like cancer and rare genetic disorders could be the key to unlocking long-term growth for the company.
Moderna’s pipeline includes several candidates in phase 3 trials, with a potential launch date on the horizon. This progress has investors excited, and Cramer is no exception. He believes that Moderna is poised for a resurgence in the biotech space, driven by the company’s innovative approach to disease treatment.
What this means
For investors, Moderna’s expanding pipeline is a signal to take a closer look at the stock. With a growing list of treatments in development, the company’s potential for long-term growth is looking brighter than ever.
If you’re an investor looking for a new biotech pick, Moderna might be worth considering. Cramer’s endorsement is a strong vote of confidence in the company’s future prospects. And with a market cap of over $40 billion, Moderna is no small player in the biotech space.
Keep an eye on Moderna’s progress as it continues to push the boundaries of mRNA technology. With Cramer’s endorsement and a strong pipeline of treatments in development, this stock is definitely worth watching.
